Johns Hopkins School of Medicine

Slusher BS, Conn, PJ Conn, Frye S, Glicksman M, Arkin M. “Bringing together the academic drug discovery community”. Nature Review Drug Discovery, 2013, Nov (12) 811

Rahn KA, Watkins CC, Alt J, Rais R, Stathis M, Grishkan I, Crainiceau CM, Pomper MG, Rojas C, Pletnikov MV, Calabresi PA, Brandt J, Barker PB, Slusher BS, Kaplin AI. “Inhibition of Glutamate Carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.” Proc Natl Acad Sci U S A. 2012, Dec 4;109(49):20101-6

Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, Slusher BS. “Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice.” Cancer Research, 2012, 71(11), 3952-3962

Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Traystman RJ, Robinson MB, Britton P, Lu M, Tortella FC, Wozniak KM, Yudkoff M, Jackson PF. “An inhibitor of NAAG hydrolysis prevents ischemic glutamate release and provides neuroprotection”. Nature Medicine, 1999, 5, 1396-1402

Wozniak KM, Vornov JJ, Mistry BM, Wu Y, Rais R, Slusher BS. “Gastrointestinal Delivery of Propofol from Fospropofol: Its Bioavailability and Activity in Rodents and Human Volunteers”. Journal Translational Medicine, 2015 May 29;13:170

Frye SV, Arkin MR, Arrowsmith CH, Conn PJ, Glicksman MA, Hull-Ryde EA, Slusher BS. “Tackling reproducibility in academic preclinical drug discovery.” Nature Reviews Drug Discovery, 2015, Nov; 14(11):733-4

Rojas C, Alt J, Ator NA, Thomas AG, Wu Y, Hin N, Wozniak K, Ferraris D, Rais R, Tsukamoto T and Slusher BS. “D-Amino-acid oxidase inhibition increases d-serine plasma levels in mouse but not in monkey or dog.” Neuropsychopharmacology, 2016, May:41(6):1610-9

Vornov JJ, Hollinger KR, Jackson PF, Wozniak KM, Farah MH, Majer P, Rais R and Slusher BS. “Still NAAG’ing After All These Years: The Continuing Pursuit of GCPII Inhibitors.” Advances in Pharmacology, 2016, 76:215-255

Rais R, Jancarik A, Tenora L, Nedelcovych M, Alt J, Englert J, Rojas C, Le A, Elgogary A, Tan J, Monincova L, Pate K, Adam RJ, Ferraris DV, Powell JD, Maje P, Slusher BS. “Discovery of 6-Diazo-5-oxo-L-norleucine (DON) prodrugs with enhanced CSF delivery in monkeys: a potential treatment for glioblastoma.” Journal of Medicinal Chemistry, 2016, Sept 22:59(18):8621-33

Elgogary A, Xu Q, Poore B, Alt J, Zimmermann SC, Zhao L, Fu J, Chen B, Xia S, Liu Y, Neisser M, Nguyen C, Lee R, Park JK, Reyes J, Hartung T, Rojas C, Rais R, Tsukamoto T, Semenza GL, Hanes J, Slusher BS, Le A. “Combination therapy with BPTES nanaoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.” Proceedings of the National Academy of Sciences, 2016, Sept 6;113(36):E5328-36

Rais R, Jancarik A, Tenora L, Nedelcovych M, Alt J, Englert J, Rojas C, Le A, Elgogary A, Tan J, Monincova L, Pate K, Adam RJ, Ferraris DV, Powell JD, Maje P, Slusher BS. “Discovery of 6-Diazo-5-oxo-L-norleucine (DON) prodrugs with enhanced CSF delivery in monkeys: a potential treatment for glioblastoma.” Journal of Medicinal Chemistry, 2016, Sept 22:59(18):8621-33

Rais R, Jiang W, Zhai H, Wozniak KM, Stathis M, Hollinger KR, Thomas AG, Rojas C, Vornov JJ, Marohn M, Li X. FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. JCI insight. 2016 Aug 4;1(12).

Nedelcovych MT, Tenora L, Kim BH, Kelschenbach J, Chao W, Hadas E, Jancarik A, Prchalova E, Zimmermann SC, Dash RP, Gadiano AJ, Garrett C, Furtmuller G, Oh B, Brandacher G, Alt J, Majer P, Volsky DJ, Rais R, Slusher BS. “N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-L-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders.” J Med Chem. 2017, Aug 24;60(16):7186-7198

Wozniak KM, Vornov JJ, Wu Y, Liu Y, Carozzi VA, Rodriguez-Menendez V, Ballarini E, Alberti P, Pozzi E, Semperboni S, Cook BM, Littlefield BA, Nomoto K, Condon K, Eckley S, DesJardins C, Wilson L, Jordan MA, Feinstein SC, Cavaletti G, Polydefkis M, and Slusher BS. “Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery.” Cancer Research, 2018, Feb 1;78(3):817-29

Rojas C, Barnaeva E, Thomas AG, Hu X, Southall N, Marugan J, Chaudhuri AD, Yoo SW, Hin N, Stepanek O, Wu Y. Slusher BS. “DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation.” Scientific Reports, 2018, Dec 1;8(1):17715

Lemberg KM, Vornov JJ, Rais R, Slusher BS. “We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine.” Molecular Cancer Therapeutics, 2018 Sep 1;17(9):1824-32

Zhu X, Nedelcovych MT, Thomas AG, Hasegawa Y, Moreno-Megui A, Coomer W, Vohra V, Saito A, Perez G, Wu Y, Alt J. Slusher BS, Kamiya A. “JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress.” Neuropsychopharmacology, 2018, Aug 01-12

Tenora L, Alt J, Dash RP, Gadiano AJ, Novotna K, Veeravalli V, Lam J, Kirkpatrick QR, Lemberg KM, Majer P, Rais R, Slusher BS. “Tumor-Targeted Delivery of 6-Diazo-5-oxo-I-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.” J Med Chem, 2019, Apr 11:62(7):3524-3538